Editas Medicine Inc (EDIT)
2.78
-0.18
(-6.08%)
USD |
NASDAQ |
Nov 14, 16:00
2.80
+0.02
(+0.72%)
After-Hours: 17:58
Editas Medicine Research and Development Expense (Quarterly): 47.64M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 47.64M |
| June 30, 2024 | 54.21M |
| March 31, 2024 | 48.79M |
| December 31, 2023 | 69.56M |
| September 30, 2023 | 40.51M |
| June 30, 2023 | 29.78M |
| March 31, 2023 | 37.80M |
| December 31, 2022 | 52.00M |
| September 30, 2022 | 41.33M |
| June 30, 2022 | 43.66M |
| March 31, 2022 | 37.98M |
| December 31, 2021 | 37.55M |
| September 30, 2021 | 29.26M |
| June 30, 2021 | 33.75M |
| March 31, 2021 | 41.94M |
| December 31, 2020 | 61.50M |
| September 30, 2020 | 33.92M |
| June 30, 2020 | 28.01M |
| March 31, 2020 | 34.57M |
| December 31, 2019 | 34.79M |
| Date | Value |
|---|---|
| September 30, 2019 | 22.70M |
| June 30, 2019 | 23.56M |
| March 31, 2019 | 15.84M |
| December 31, 2018 | 19.19M |
| September 30, 2018 | 17.44M |
| June 30, 2018 | 32.72M |
| March 31, 2018 | 21.30M |
| December 31, 2017 | 26.42M |
| September 30, 2017 | 20.40M |
| June 30, 2017 | 17.32M |
| March 31, 2017 | 19.02M |
| December 31, 2016 | 26.84M |
| September 30, 2016 | 10.83M |
| June 30, 2016 | 10.43M |
| March 31, 2016 | 8.882M |
| December 31, 2015 | 5.826M |
| September 30, 2015 | 3.85M |
| June 30, 2015 | 7.282M |
| March 31, 2015 | 1.888M |
| December 31, 2014 | 2.395M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
28.01M
Minimum
Jun 2020
69.56M
Maximum
Dec 2023
41.93M
Average
39.24M
Median
Research and Development Expense (Quarterly) Benchmarks
| EyePoint Pharmaceuticals Inc | 29.82M |
| Cassava Sciences Inc | 17.68M |
| Adverum Biotechnologies Inc | 20.44M |
| Regenxbio Inc | 54.43M |
| Apellis Pharmaceuticals Inc | 88.57M |